Trevi Therapeutics, Inc. NASDAQ:TRVI

Founder-led company

Trevi Therapeutics stock price today

$7.33
+3.06
+71.66%
Financial Health
0
1
2
3
4
5
6
7
8
9

Trevi Therapeutics stock price monthly change

+52.50%
month

Trevi Therapeutics stock price quarterly change

+52.50%
quarter

Trevi Therapeutics stock price yearly change

+196.53%
year

Trevi Therapeutics key metrics

Market Cap
357.46M
Enterprise value
21.37M
P/E
-4.26
EV/Sales
N/A
EV/EBITDA
-0.49
Price/Sales
N/A
Price/Book
0.31
PEG ratio
-0.29
EPS
-0.33
Revenue
N/A
EBITDA
-36.80M
Income
-33.56M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Trevi Therapeutics stock price history

Trevi Therapeutics stock forecast

Trevi Therapeutics financial statements

Average Price Target
Last Year

$6

Potential downside: -18.14%

Based on estimate of 2 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Trevi Therapeutics, Inc. (NASDAQ:TRVI): Profit margin
Jun 2023 0 -7.14M
Sep 2023 0 -7.69M
Dec 2023 176K -7.82M -4443.75%
Mar 2024 0 -10.90M
0%
Yield TTM
Trevi Therapeutics, Inc. (NASDAQ:TRVI): Payout ratio
Payout ratio 0%
Trevi Therapeutics, Inc. (NASDAQ:TRVI): Dividend Yield
2019 5.09%
2020
2021
2022
2023
Trevi Therapeutics, Inc. (NASDAQ:TRVI): Debt to assets
Jun 2023 100977000 5.90M 5.85%
Sep 2023 95896000 6.28M 6.56%
Dec 2023 89403000 6.85M 7.67%
Mar 2024 78559000 6.22M 7.92%
Trevi Therapeutics, Inc. (NASDAQ:TRVI): Cash Flow
Jun 2023 -9.87M 19.63M -7.66K
Sep 2023 -7.27M 17.98M 1.51K
Dec 2023 -6.35M 12.84M -54
Mar 2024 -10.46M -8.09M -28K

Trevi Therapeutics alternative data

Trevi Therapeutics, Inc. (NASDAQ:TRVI): Employee count
Aug 2023 22
Sep 2023 30
Oct 2023 30
Nov 2023 30
Dec 2023 25
Jan 2024 25
Feb 2024 25
Mar 2024 25
Apr 2024 25
May 2024 25
Jun 2024 25
Jul 2024 25

Trevi Therapeutics other data

13.98% -48.70%
of TRVI is owned by hedge funds
9.02M -34.16M
shares is hold by hedge funds

Trevi Therapeutics, Inc. (NASDAQ:TRVI): Insider trades (number of shares)
Period Buy Sel
Oct 2023 0 785
May 2024 0 87333
Aug 2024 0 52556
Sep 2024 0 61180
Transaction Date Insider Security Shares Price per share Total value Source
Option
GALLETTA CHRISTOPHER officer: See Remarks
Stock Option (right to buy) 15,000 $0.51 $7,665
Option
GALLETTA CHRISTOPHER officer: See Remarks
Common Stock 15,000 $0.51 $7,665
Option
GOOD JENNIFER L director, officer.. Common Stock 1,840 $1.43 $2,631
Sale
GOOD JENNIFER L director, officer.. Common Stock 1,840 $3.04 $5,586
Option
GOOD JENNIFER L director, officer.. Stock Option (right to buy) 1,840 $1.43 $2,631
Option
GOOD JENNIFER L director, officer.. Common Stock 4,219 $1.43 $6,033
Sale
GOOD JENNIFER L director, officer.. Common Stock 4,219 $3.03 $12,784
Option
GOOD JENNIFER L director, officer.. Stock Option (right to buy) 4,219 $1.43 $6,033
Option
GOOD JENNIFER L director, officer.. Common Stock 40,277 $1.43 $57,596
Sale
GOOD JENNIFER L director, officer.. Common Stock 40,277 $3.11 $125,302
Patent
Application
Filling date: 9 May 2022 Issue date: 25 Aug 2022
Application
Filling date: 24 Mar 2022 Issue date: 14 Jul 2022
Application
Filling date: 23 Jul 2019 Issue date: 23 Jan 2020
Application
Filling date: 10 Jul 2019 Issue date: 16 Jan 2020
Monday, 16 December 2024
prnewswire.com
Thursday, 12 December 2024
benzinga.com
prnewswire.com
Tuesday, 3 December 2024
prnewswire.com
Thursday, 21 November 2024
prnewswire.com
Wednesday, 6 November 2024
prnewswire.com
Wednesday, 30 October 2024
prnewswire.com
Monday, 21 October 2024
prnewswire.com
Tuesday, 15 October 2024
prnewswire.com
Thursday, 3 October 2024
prnewswire.com
Monday, 30 September 2024
prnewswire.com
Thursday, 26 September 2024
prnewswire.com
Friday, 6 September 2024
marketbeat.com
Wednesday, 4 September 2024
prnewswire.com
Wednesday, 28 August 2024
prnewswire.com
Sunday, 11 August 2024
seekingalpha.com
Thursday, 8 August 2024
prnewswire.com
Thursday, 1 August 2024
prnewswire.com
Tuesday, 2 July 2024
prnewswire.com
Saturday, 11 May 2024
Seeking Alpha
Thursday, 9 May 2024
PRNewsWire
Wednesday, 1 May 2024
PRNewsWire
Thursday, 18 April 2024
Zacks Investment Research
Thursday, 4 April 2024
Zacks Investment Research
Wednesday, 20 March 2024
Seeking Alpha
Wednesday, 17 January 2024
Zacks Investment Research
Thursday, 30 November 2023
Zacks Investment Research
Tuesday, 14 November 2023
Zacks Investment Research
Sunday, 12 November 2023
Seeking Alpha
Wednesday, 11 October 2023
Zacks Investment Research
  • What's the price of Trevi Therapeutics stock today?

    One share of Trevi Therapeutics stock can currently be purchased for approximately $7.33.

  • When is Trevi Therapeutics's next earnings date?

    Unfortunately, Trevi Therapeutics's (TRVI) next earnings date is currently unknown.

  • Does Trevi Therapeutics pay dividends?

    No, Trevi Therapeutics does not pay dividends.

  • How much money does Trevi Therapeutics make?

    Trevi Therapeutics has a market capitalization of 357.46M.

  • What is Trevi Therapeutics's stock symbol?

    Trevi Therapeutics, Inc. is traded on the NASDAQ under the ticker symbol "TRVI".

  • What is Trevi Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Trevi Therapeutics?

    Shares of Trevi Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Trevi Therapeutics's key executives?

    Trevi Therapeutics's management team includes the following people:

    • Ms. Jennifer L. Good Co-Founder, Chief Executive Officer, Pres & Director(age: 60, pay: $662,640)
    • Dr. Thomas R. Sciascia Co-Founder & Chief Medical Officer(age: 72, pay: $476,250)
  • Is Trevi Therapeutics founder-led company?

    Yes, Trevi Therapeutics is a company led by its founders Ms. Jennifer L. Good and Dr. Thomas R. Sciascia.

  • How many employees does Trevi Therapeutics have?

    As Jul 2024, Trevi Therapeutics employs 25 workers.

  • When Trevi Therapeutics went public?

    Trevi Therapeutics, Inc. is publicly traded company for more then 6 years since IPO on 7 May 2019.

  • What is Trevi Therapeutics's official website?

    The official website for Trevi Therapeutics is trevitherapeutics.com.

  • Where are Trevi Therapeutics's headquarters?

    Trevi Therapeutics is headquartered at 195 Church Street, New Haven, CT.

  • How can i contact Trevi Therapeutics?

    Trevi Therapeutics's mailing address is 195 Church Street, New Haven, CT and company can be reached via phone at +20 3 3042499.

  • What is Trevi Therapeutics stock forecast & price target?

    Based on 2 Wall Street analysts` predicted price targets for Trevi Therapeutics in the last 12 months, the avarage price target is $6. The average price target represents a -18.14% change from the last price of $7.33.

Trevi Therapeutics company profile:

Trevi Therapeutics, Inc.

trevitherapeutics.com
Exchange:

NASDAQ

Full time employees:

27

Industry:

Biotechnology

Sector:

Healthcare

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

195 Church Street
New Haven, CT 06510

CIK: 0001563880
ISIN: US89532M1018
CUSIP: 89532M101